TCA
IONS icon

Troluce Capital Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Troluce Capital Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$401K – 62
2024
Q3 		$401K Buy
+10,000
New +$465K 0.02% 77

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Troluce Capital Advisors's IONS Position: Q4 2024 in Review

Troluce Capital Advisors sold out of Ionis Pharmaceuticals (IONS) in Q4 2024, closing a stake of 10,000 shares — an estimated $401K sold.

Troluce Capital Advisors first reported a position in IONS in Q3 2024 and held it in 1 quarter. The position peaked at $401K in Q3 2024. 354 funds tracked by Wall St. Rank hold IONS as of Q4 2024.

  • Troluce Capital Advisors reported no remaining Ionis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Troluce Capital Advisors sold 10,000 Ionis Pharmaceuticals shares in Q4 2024, an estimated $401K.
  • Troluce Capital Advisors first reported a position in Ionis Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Troluce Capital Advisors's Ionis Pharmaceuticals position peaked at $401K in Q3 2024.
  • 354 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2024.

Based on Troluce Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.